Point-of-care screening,
using digital microfluidics,
provides accurate,
low blood volume,
and affordable technology
for rapid newborn glucose-6-phosphate dehydrogenase enzyme screening
that could guide clinicians before infants’ discharge
from well-child nurseries
and meet existing American Academy
of Pediatrics’ recommendation